Evidence map›Paper›PMID 41077583›Full record

ArticleJournal of hematology & oncology2025

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity.

Yan-Ruide Li, Xinyuan Shen, Yichen Zhu, Zhe Li, Ryan Hon, Yanxin Tian, Jie Huang, Annabel S Zhao, Nathan Y Ma, Catherine Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yan-Ruide LiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Xinyuan ShenDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Yichen ZhuDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Zhe LiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Ryan HonDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Yanxin TianDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Jie HuangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Annabel S ZhaoDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Nathan Y MaDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Catherine ZhangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
David LinDivision of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Karine SargsyanOncoBiobank, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Yuan YuanDivision of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Lili YangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA. liliyang@ucla.edu.

Funding

California Institute for Regenerative Medicine DISC2-11157University of California, Los Angeles UCLA BSCRC Innovation AwardUniversity of California, Los Angeles UCLA MIMG M. John Pickett Post-Doctoral Fellow AwardU.S. Department of Defense CA200456
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of ER, PR, and HER2 expression. Its aggressive behavior, high degree of tumor heterogeneity, and immunosuppressive tumor microenvironment (TME) are associated with poor clinical outcomes, rapid disease progression, and limited therapeutic options. Although chimeric antigen receptor (CAR)-engineered T cell therapy has shown certain promise, its applicability in TNBC is hindered by antigen escape, TME-mediated suppression, and the logistical constraints of autologous cell production.

methodsIn this study, we employed hematopoietic stem and progenitor cell (HSPC) gene engineering and a feeder-free HSPC differentiation culture to generate allogeneic IL-15-enhanced, mesothelin-specific CAR-engineered invariant natural killer T (

resultsThese cells demonstrated robust and multifaceted antitumor activity against TNBC, mediated by CAR- and NK receptor-dependent cytotoxicity, as well as selective targeting of CD1d

conclusionsTogether, these results support

Indexed as

GPI-Linked ProteinsHematopoietic Stem CellsImmunotherapy, AdoptiveNatural Killer T-CellsReceptors, Chimeric AntigenTriple Negative Breast NeoplasmsAnimalsAntigens, CD34Cell Line, TumorFemaleFetal BloodHumansMesothelinMiceMice, Inbred NODMice, SCIDAntigens, CD34GPI-Linked ProteinsMesothelinReceptors, Chimeric AntigenAllogeneic CAR-NKT cellsAllogeneic cell therapyAllorejectionCRISPR-Cas9 gene editingHLA ablationMesothelin-targeting CAR (MCAR)Metastatic modelMultiple tumor targeting mechanismOff-the-shelfOrthotopic modelPotent antitumor activityTriple-negative breast cancer (TNBC)Tumor-associated macrophage (TAM)Tumor microenvironment (TME)

Identifiers

PMID41077583
PMCPMC12516852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.